1-(N-乙酰氨基)环己基羧酸 | 4854-47-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 1-(N-乙酰氨基)环己基羧酸
• 英文名称: 1-(N-acetylamino)cyclohexylcarboxylic acid
• 英文别名: 1-acetamidocyclohexanecarboxylic acid；1-acetylamino-cyclohexanecarboxylic acid；1-Acetamino-cyclohexan-carbonsaeure-(1)；1-Acetylamino-cyclohexan-1-carbonsaeure；1-acetamidocyclohexane-1-carboxylic Acid
• CAS: 4854-47-1
• 化学式: C₉H₁₅NO₃
• mdl: MFCD09933315
• 分子量: 185.223
• InChiKey: APYLGUGGCARYFQ-UHFFFAOYSA-N

物化性质

• 熔点：
  202 °C
• 沸点：
  419.9±24.0 °C(Predicted)
• 密度：
  1.16±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.777
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(N-乙酰氨基)环己基羧酸 在 乙酸酐 作用下， 反应 0.5h， 生成 2-methyl-3-oxa-1-aza-spiro[4.5]dec-1-en-4-one
  参考文献：
  名称：

  Branquet; Pacheco; Cier, Bulletin de la Societe Chimique de France, 1965, vol. 10, p. 2942 - 2954

  摘要：

  DOI：
• 作为产物：
  描述：

  N-(1-氰基环己基)乙酰胺 在 盐酸 作用下， 生成 1-(N-乙酰氨基)环己基羧酸
  参考文献：
  名称：

  Granger,R. et al., Comptes Rendus Hebdomadaires des Seances de l'Academie des Sciences, 1960, vol. 250, p. 4378 - 4380

  摘要：

  DOI：
• 作为试剂：
  描述：

  1,1,1-trifluoro-N-(1-methoxybutan-2-yl)methanesulfonamide 、 4-甲氧甲酰苯硼酸频哪醇酯 在 1-(N-乙酰氨基)环己基羧酸 、 palladium diacetate 、 sodium carbonate 、 silver carbonate 、 对苯醌 作用下， 以 2-甲基-2-丁醇 、 水 为溶剂， 反应 24.0h， 生成 methyl (R)-4-(4-methoxy-3-((trifluoromethyl)sulfonamido)butyl)benzoate
  参考文献：
  名称：

  通过 Pd(II)/Pd(0) 催化对烷基胺进行对映选择性 γ-C(sp3)-H 活化

  摘要：

  使用手性乙酰基保护的氨基甲基恶唑啉配体 (APAO) 首次实现了 Pd(II) 催化的烷基胺通过去对称化和动力学拆分的对映选择性 γ-C(sp3)-H 交叉偶联。多种芳基和乙烯基硼试剂可用作偶联伙伴。手性γ-芳基化烷基胺产物进一步转化为手性2-取代的1,2,3,4-四氢喹啉和螺-吡咯烷，作为天然产物和生物活性分子中的重要结构基序。

  DOI：

  10.1021/jacs.8b01094

文献信息

• [EN] CRF RECEPTOR ANTAGONISTS AND METHODS OF USE<br/>[FR] ANTAGONISTES DU RÉCEPTEUR CRF ET MÉTHODES D'UTILISATION
  申请人：NEUROCRINE BIOSCIENCES INC

  公开号：WO2021062246A1

  公开（公告）日：2021-04-01

  Compounds are provided herein, as well as related preparations, compositions and methods for treating diseases and/or disorders that would benefit from the same such as congenital adrenal hyperplasia (CAH).

  本文提供了化合物，以及相关的制剂、组合物和治疗方法，用于治疗需要这些治疗的疾病和/或疾病，例如先天性肾上腺皮质增生症（CAH）。
• Synthesis of Sterically Hindered <i>N</i>-Acylated Amino Acids from <i>N</i>-Carboxyanhydrides
  作者：Gabriel Schäfer、Jeffrey W. Bode

  DOI：10.1021/ol500523n

  日期：2014.3.7

  Sterically hindered N-acyl, gem-disubstituted amino acids are easily prepared via the addition of organometallic reagents to N-carboxyanhydrides (NCA). The process tolerates a wide variety of functional groups and allows the synthesis of amide products not readily accessible by traditional acylation chemistry. The existence of an isocyanate intermediate was established by in situ IR spectroscopy.
• Straightforward, racemization-free synthesis of peptides with fairly to very bulky di- and trisubstituted glycines
  作者：Filipa C.S.C. Pinto、Sílvia M.M.A. Pereira-Lima、Hernâni L.S. Maia

  DOI：10.1016/j.tet.2009.09.022

  日期：2009.11

  Several fully protected tri- and pentapeptides containing a central symmetrical alpha,alpha-dialkyl glycine residue, with the alkyl group varying from methyl or ethyl to benzyl, were synthesized in good yields by a strategy based on the Ugi-Passerini reaction. Each Ugi-Passerini adduct was selectively cleaved and the product submitted to an assisted N,N'-dicyclohehylcarbodiimide coupling to an amino acid or dipeptide ester, respectively. Tripeptides as the above but containing a 4-methoxybenzyl group at the nitrogen atom of the central residue were also synthesized in fair to good yields by N-[(1H-benzotriazol-1-yl)(dimethylamino)methylene]-N-methylmethanaminium hexafluorophosphate N-oxide assisted couplings. The results reported here show that our strategy is appropriate for routine synthesis of peptides incorporating these moieties. (C) 2009 Elsevier Ltd. All rights reserved.
• CARBOXYL- OR HYDROXYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES
  申请人：F. Hoffmann-La Roche AG

  公开号：EP2225221A2

  公开（公告）日：2010-09-08
• [EN] CYSTEINE PROTEASE INHIBITORS<br/>[FR] INHIBITEURS DE LA CYSTEINE PROTEASE
  申请人：AXYS PHARM INC

  公开号：WO2002023784A2

  公开（公告）日：2002-03-21

  The present invention relates to compounds, compositions and methods for treating diseases associated with cysteine protease activity, particularly diseases associated with activity of cathepsins B, K, L or S.The present invention thus provides compounds of Formula (I): pharmaceutical compositions comprising compounds of Formula (I) and methods of treating diseases associated with cysteine protease activity using pharmaceutical compositions comprising compounds of Formula (I).